These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 5286449)

  • 1. Leukemia and related disorders.
    Anderson RE
    Hum Pathol; 1971 Dec; 2(4):505-14. PubMed ID: 5286449
    [No Abstract]   [Full Text] [Related]  

  • 2. [Myeloproliferative syndrome, myelofibrosis and erythrocytosis. A retrospective study].
    Retief FP; Du P Heyns A
    S Afr Med J; 1974 Dec; 48(59):2429-35. PubMed ID: 4532812
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.
    Cervantes F; Tassies D; Salgado C; Rovira M; Pereira A; Rozman C
    Acta Haematol; 1991; 85(3):124-7. PubMed ID: 2042444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
    Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
    Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.
    Kutti J; Ridell B
    Pathol Biol (Paris); 2001 Mar; 49(2):164-6. PubMed ID: 11317963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms.
    Gross-Davis CA; Heavner K; Frank AL; Newschaffer C; Klotz J; Santella RM; Burstyn I
    Int J Environ Res Public Health; 2015 Feb; 12(3):2465-85. PubMed ID: 25719551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [MYELOPROLIFERATIVE SYNDROMES].
    PIRESWDA F
    Folha Med; 1964 Apr; 48():195-201. PubMed ID: 14271209
    [No Abstract]   [Full Text] [Related]  

  • 8. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Myeloproliferative disorders].
    Binder D; Fehr J
    Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
    Deadmond MA; Smith-Gagen JA
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
    Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
    Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.
    Verstovsek S; Yu J; Scherber RM; Verma S; Dieyi C; Chen CC; Parasuraman S
    Leuk Lymphoma; 2022 Mar; 63(3):694-702. PubMed ID: 34689695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spectrum of myeloproliferative disorders.
    Gilbert HS
    Med Clin North Am; 1973 Mar; 57(2):355-93. PubMed ID: 4570933
    [No Abstract]   [Full Text] [Related]  

  • 14. Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.
    Shrestha R; Giri S; Armitage JO; Bhatt VR
    Future Oncol; 2017 Jun; 13(14):1239-1246. PubMed ID: 28589759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An addition to geographic hematology: chronic myeloproliferative diseases are infrequent in Mexican Mestizos.
    Ruiz-Argüelles GJ; López-Martínez B; Lobato-Mendizábal E; Ruiz-Delgado GJ
    Int J Hematol; 2002 Jun; 75(5):499-502. PubMed ID: 12095150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
    Greenberg PL
    Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
    [No Abstract]   [Full Text] [Related]  

  • 17. An association of myeloproliferative neoplasms and obliterative portal venopathy.
    Mayer JE; Schiano TD; Fiel MI; Hoffman R; Mascarenhas JO
    Dig Dis Sci; 2014 Jul; 59(7):1638-41. PubMed ID: 24474573
    [No Abstract]   [Full Text] [Related]  

  • 18. Contemporary approach to essential thrombocythemia and polycythemia vera.
    Aruch D; Mascarenhas J
    Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series.
    Smith CJ; Thomas JW; Ruan G; Hyun MC; Bansal R; McLaughlin N; Pardanani A; Gangat N; Go RS; Szuber N; Goyal G; Shah MV; Tefferi A
    Am J Hematol; 2021 Dec; 96(12):E464-E468. PubMed ID: 34661932
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical predictors of outcome in MPN.
    Passamonti F; Maffioli M; Merli M; Ferrario A; Caramazza D
    Hematol Oncol Clin North Am; 2012 Oct; 26(5):1101-16. PubMed ID: 23009940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.